A Radiomics Nomogram for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma
Conclusions: The nomogram incorporating clinicoradiological risk factors and radiomic features derived from HBP images achieved satisfactory preoperative prediction of the individualized risk of MVI in patients with HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - November 27, 2018 Category: Cancer & Oncology Source Type: research

Erratum
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - November 2, 2018 Category: Cancer & Oncology Source Type: research

Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
Conclusions: In Dutch HCC patients treated with sorafenib, the combined presence of low SMM and low TATI was associated with impaired survival, independent of known prognostic factors. CT assessment of body composition may provide additional prognostic information prior to sorafenib treatment.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - November 2, 2018 Category: Cancer & Oncology Source Type: research

Contents Vol. 7, 2018
Liver Cancer 2018;7:I –VI (Source: Liver Cancer)
Source: Liver Cancer - October 26, 2018 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2018;7:372 –372 (Source: Liver Cancer)
Source: Liver Cancer - October 18, 2018 Category: Cancer & Oncology Source Type: research

The APPLE Association President's Message
Liver Cancer 2018;7:373 –373 (Source: Liver Cancer)
Source: Liver Cancer - October 18, 2018 Category: Cancer & Oncology Source Type: research

Apple 2019
Liver Cancer 2018;7:374 –374 (Source: Liver Cancer)
Source: Liver Cancer - October 18, 2018 Category: Cancer & Oncology Source Type: research

Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma
Conclusions: Inflammatory scores obtained before sorafenib treatment initiation are associated with OS in advanced HCC. Their combination with other risk factors improves prediction of 3- and 12-month survival, which could guide treatment decisions in selected patient subgroups.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: research

Erratum
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - September 10, 2018 Category: Cancer & Oncology Source Type: research

Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model
Conclusions: We demonstrated that DDP4i prevented the progression of NASH-related HCC in a mouse model. Furthermore, metabolome analysis revealed that DDP4i downregulated the pentose phosphate pathway with suppression of the p62/Keap1/Nrf2 pathway. Thus, DDP4i may prevent tumor progression through inhibition of metabolic reprogramming in NASH-related HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - September 7, 2018 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2018;7:304 –304 (Source: Liver Cancer)
Source: Liver Cancer - September 7, 2018 Category: Cancer & Oncology Source Type: research

Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - August 24, 2018 Category: Cancer & Oncology Source Type: research

Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - August 23, 2018 Category: Cancer & Oncology Source Type: research

Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - August 23, 2018 Category: Cancer & Oncology Source Type: research

Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency
Conclusions: K19-proficient HCC exhibited poor prognosis owing to extrahepatic recurrence, with molecular signatures differing from those in conventional cancer stem cells, providing novel insights of the heterogeneity underlying tumor development.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - August 21, 2018 Category: Cancer & Oncology Source Type: research